Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis  Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

Slides:



Advertisements
Similar presentations
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact  C.R. Hansen, T. Pressler, W. Ridderberg, H.K.
Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis  E.
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
K. Budding, E.A. van de Graaf, T. Hoefnagel, C.E. Hack, H.G. Otten 
Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai 
Infections in Patients with Cystic Fibrosis
Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients  Helle Krogh Johansen, Samuel.
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
William G. Flight, Jonathan Shaw, Susan Johnson, A
K. L. Nash, M. E. Allison, D. McKeon, D. J. Lomas, C. S. Haworth, D
Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients  Luis Pablo Gravina, Carolina Crespo, Hilda.
Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Katarine Egressy, Michaelene Jansen, Keith C. Meyer 
Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation 
Pseudomonas aeruginosa in cystic fibrosis: Pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease  Malin Carlsson, Swati.
Patrick O. Sobande, James D. Acton, Raouf S. Amin, Jeanne Weiland 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Journal of Cystic Fibrosis
D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M
Ludger Dorlöchter, Malin Carlsson, Edda J. Olafsdottir, Ola D
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
John Widger, Sarath Ranganathan, Philip J. Robinson 
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF  Christina Schjellerup Dalbøge, Tacjana.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
Vitamin A and lung function in CF
Rajeev Soni, Catherine J. Dobbin, Maree A. Milross, Iven H
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
A.H. Gifford  Journal of Cystic Fibrosis 
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis  D.W. Reid, R. Latham, I.L.
Valerie Waters, Eshetu G
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function  Julia Seyfarth, Sutharsan Sivagurunathan,
Nasal polyposis in lung transplant recipients with cystic fibrosis
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands 
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients  Valerie Waters, Eshetu G. Atenafu, Annie.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R
Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis  Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States  Kathleen J. Ramos, Bradley S. Quon, Kevin.
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis  Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält, Lena Mared, Peter Meyer, Allan Wiik, Jörgen Wieslander, Mårten Segelmark  Journal of Cystic Fibrosis  Volume 6, Issue 3, Pages 228-233 (May 2007) DOI: 10.1016/j.jcf.2006.10.005 Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 BPI-ANCA according to lung function. The BPI-ANCA values are shown on a logarithmized scale. All patients who were old enough to perform lung function test and who were not lung transplanted were included in the analysis. Levels of BPI-ANCA in serum of patients with severe lung damage (FEV1%pred <50%), moderate lung damage (FEV1%pred 50–80%) and preserved lung function (FEV1%pred >80%). Swedish patients are shown with shaded boxes and Danish patients are shown with open boxes. The dashed line indicates the positive cut off level (67 U/L). The Kruskal-Wallis test was used on non-logarithmized values to compare the median values. Journal of Cystic Fibrosis 2007 6, 228-233DOI: (10.1016/j.jcf.2006.10.005) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 (a) Swedish patients. (b) Danish patients. The patients were divided into age groups in order to create a fictive time scale. The lines indicate percentages of patients who are chronically colonized with Pseudomonas aeruginosa, patients with positive serum levels of BPI-ANCA and patients with severe lung damage. The youngest groups contain patients below 5 years of age, and the oldest contain patients over the age of 36. Severe lung damage was defined as forced expiratory volume in 1 s (FEV1) below 50% of the predicted value or had undergone lung transplantation, positive BPI-ANCA: >67 U/L. Journal of Cystic Fibrosis 2007 6, 228-233DOI: (10.1016/j.jcf.2006.10.005) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Serum levels of BPI-ANCA before and after lung transplantation in seven patients. The dashed line indicates the positive cut off level for BPI-ANCA (67 U/L). Journal of Cystic Fibrosis 2007 6, 228-233DOI: (10.1016/j.jcf.2006.10.005) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions